for people ages 18 years and up (full criteria)
at Fresno, California and other locations
study started
completion around



The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Official Title

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis


Plaque Psoriasis, Psoriasis, Deucravacitinib, JNJ-77242113


You can join if…

Open to people ages 18 years and up

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

You CAN'T join if...

  • Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention
  • Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study


  • UCSF Fresno accepting new patients
    Fresno California 93701 United States
  • T Joseph Raoof Md Inc accepting new patients
    Encino California 91436 United States


accepting new patients
Start Date
Completion Date
Janssen Research & Development, LLC
Phase 3 Psoriasis Research Study
Study Type
Expecting 675 study participants
Last Updated